sharecast

{{ storiesRelated.title }}

Aim Bulletin
05 Mar
dl greatland gold plc aim basic materials basic resources precious metals and mining gold mining logo 20230316
Greatland reports decent progress in interim report

Greatland Gold reported progress at its flagship Havieron gold-copper project in an interim report on Thursday, and updates on exploration activities across its Australian portfolio.

05 Mar
dl johnson service group aim workwear textiles horeca catering industry johnsons the cleaners logo
Acquisitions help drive strong growth at Johnson Service Group

Johnson Service Group released a strong set of preliminary results for 2023 on Tuesday, with total revenue increasing 20. 6% to reach £465. 3m.

05 Mar
dl dotdigital group plc aim dot digital technology software and computer services consumer digital services logo 20230307
DotDigital reports positive set of interim results

Customer experience and data platform (CDXP) provider dotDigital Group reported a positive set of interim results on Tuesday, with a 15% increase in group revenue to £38. 7m, and a solid 11% organic revenue increase excluding the acquisition of Fresh Relevance.

05 Mar
dl somero enterprises aim laser concrete screeding technology non residential construction building logo
Somero confident despite weaker set of full-year results

Concrete levelling equipment specialist Somero Enterprises reported a weaker set of final results for 2023 on Tuesday, following declines in its core North American market.

05 Mar
dl ondine biomedical aim bio pharmaceutical research development pharma clinical medical logo
Ondine Biomedical assessing Steriwave with Yorkshire partners

Ondine Biomedical announced on Tuesday that it is joining forces with the Mid Yorkshire Teaching NHS Trust, Health Innovation Yorkshire and Humber, and the York Health Economics Consortium (YHEC) to assess the potential cost savings associated with using its ‘Steriwave’ technology.

05 Mar
dl maxcyte inc aim health care healthcare pharmaceuticals and biotechnology logo 20230316
MaxCyte flags lower 2023 revenue, flat 2024 growth

Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41. 1m and $41. 3m, down from $44. 3m in 2022.